Health Characteristics and Aspirin Use in Participants at the Baseline of the ASPirin in Reducing Events in the Elderly - eXTension (ASPREE-XT) Observational Study.
ASPREE
Aspirin
Healthy aging
Observational
Journal
Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
08
12
2022
revised:
18
04
2023
accepted:
11
05
2023
pmc-release:
01
07
2024
medline:
14
6
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Aspirin as a primary preventative in healthy older adults did not prolong disability-free survival in the ASPREE randomized trial. Observational studies following randomized trials allow assessment of benefits and harms which may not appear during the trial. We describe health characteristics, physical function, and aspirin use in the ASPREE-eXTension (ASPREE-XT) observational study cohort. Descriptive statistics compared health characteristics of those consented to ASPREE-XT at their first post-trial baseline (XT01) to corresponding ASPREE baseline values, and to those not consented. Likelihood of an indication for aspirin was assessed in participants reporting aspirin use at XT01. 16,317 (93%) of the remaining and eligible 17,546 ASPREE participants were consented into ASPREE-XT; 14,894 completed XT01. Mean participant age had increased from 74.9 to 80.6 years. Overall health and physical function declined from the original ASPREE baseline; more participants were living alone, there was higher prevalence of chronic kidney disease, diabetes, and frailty, grip strength was lower and gait speed slower. Those not consented into ASPREE-XT were slightly older, and had lower cognitive scores and higher prevalence of age-related conditions than those who continued. 1015/11,717 (8.7%) participants without an apparent indication for aspirin reported using aspirin at XT01. The ASPREE-XT cohort was slightly less healthy at the XT01 visit than at ASPREE trial initiation, and rates of aspirin use without indication were similar to ASPREE baseline. Participants will be followed long-term to investigate aspirin's potential legacy towards dementia and cancer prevention and explore determinants of healthy aging.
Sections du résumé
BACKGROUND
Aspirin as a primary preventative in healthy older adults did not prolong disability-free survival in the ASPREE randomized trial. Observational studies following randomized trials allow assessment of benefits and harms which may not appear during the trial. We describe health characteristics, physical function, and aspirin use in the ASPREE-eXTension (ASPREE-XT) observational study cohort.
METHODS
Descriptive statistics compared health characteristics of those consented to ASPREE-XT at their first post-trial baseline (XT01) to corresponding ASPREE baseline values, and to those not consented. Likelihood of an indication for aspirin was assessed in participants reporting aspirin use at XT01.
RESULTS
16,317 (93%) of the remaining and eligible 17,546 ASPREE participants were consented into ASPREE-XT; 14,894 completed XT01. Mean participant age had increased from 74.9 to 80.6 years. Overall health and physical function declined from the original ASPREE baseline; more participants were living alone, there was higher prevalence of chronic kidney disease, diabetes, and frailty, grip strength was lower and gait speed slower. Those not consented into ASPREE-XT were slightly older, and had lower cognitive scores and higher prevalence of age-related conditions than those who continued. 1015/11,717 (8.7%) participants without an apparent indication for aspirin reported using aspirin at XT01.
CONCLUSIONS
The ASPREE-XT cohort was slightly less healthy at the XT01 visit than at ASPREE trial initiation, and rates of aspirin use without indication were similar to ASPREE baseline. Participants will be followed long-term to investigate aspirin's potential legacy towards dementia and cancer prevention and explore determinants of healthy aging.
Identifiants
pubmed: 37196887
pii: S1551-7144(23)00154-4
doi: 10.1016/j.cct.2023.107231
pmc: PMC10330669
mid: NIHMS1904145
pii:
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107231Subventions
Organisme : NIA NIH HHS
ID : U01 AG029824
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG062682
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors declare no conflicts of interest in the publication of this manuscript.
Références
N Engl J Med. 2018 Oct 18;379(16):1509-1518
pubmed: 30221597
JAMA. 2022 Apr 26;327(16):1577-1584
pubmed: 35471505
Lancet. 2012 Apr 28;379(9826):1602-12
pubmed: 22440946
N Engl J Med. 2018 Oct 18;379(16):1529-1539
pubmed: 30146931
Int J Stroke. 2017 Jan;12(1):108-113
pubmed: 27634976
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
Contemp Clin Trials Commun. 2017 Jun;6:105-114
pubmed: 28736754
Ann Intern Med. 2016 Jun 21;164(12):836-45
pubmed: 27064677
JAMA Netw Open. 2021 Jun 1;4(6):e2112210
pubmed: 34152419
Contemp Clin Trials. 2016 Jan;46:60-66
pubmed: 26611434
JAMA Oncol. 2022 Oct 1;8(10):1392-1394
pubmed: 35900749
Ann Intern Med. 2019 Oct 15;171(8):596-598
pubmed: 31330542
J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1586-1593
pubmed: 28329340
Int J Epidemiol. 2019 Aug 1;48(4):1048-1049h
pubmed: 30624660
Am J Prev Cardiol. 2021 Sep 22;8:100256
pubmed: 34632437
Trials. 2018 Jan 11;19(1):29
pubmed: 29325575
Genet Med. 2020 Nov;22(11):1883-1886
pubmed: 32606442
Inj Prev. 2016 Aug;22(4):297-301
pubmed: 26002770
Trials. 2018 May 30;19(1):298
pubmed: 29843774
PLoS One. 2019 Dec 27;14(12):e0226868
pubmed: 31881040
BMC Neurol. 2012 Feb 08;12:3
pubmed: 22315948
Circulation. 2019 Sep 10;140(11):e596-e646
pubmed: 30879355
Lancet. 2018 Sep 22;392(10152):1036-1046
pubmed: 30158069